The specificity of DP IV for natural substrates is peptide structure determined

Advances in Experimental Medicine and Biology

Volumn 524, Issue , 2003, Pages 57-63

  Kühn Wache, Kerstin ^a   Hoffmann, Torsten ^a   Manhart, Susanne ^a   Brandt, W ^b   Demuth, Hans Ulrich ^a  

^a PROBIODRUG AG   (Germany)

^b LEIBNIZ INSTITUTE OF PLANT BIOCHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

CONFERENCE PAPER; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME SUBSTRATE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD26; BINDING SITES; GASTRIC INHIBITORY POLYPEPTIDE; HUMANS; KINETICS; MAMMALS; PEPTIDE FRAGMENTS; PEPTIDES; SUBSTRATE SPECIFICITY;

EID: 0037687917     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (8)

1. Bongers, J., Lambros, T., Ahmad, M. and Heimer, E.P.; 1992, Kinetics of dipeptidyl peptidase IV proteolysis of growth hormone-releasing factor and analogs. Biochim. Biophys. Acta: 1122-147.
2. DeMeester, I., Korom, S., Van Damme, J. and Scharpé, S., 1999, CD26, let it cut or cut it down. Immunol Today 20: 367-375.
3. Kieffer, T.J., McIntosh, C.H. and Pederson, R.A., 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (8): 3585-3596.
4. Hinke, S.A., Pospisilik, J.A., Demuth, H.-U., Mannhart, S., Kühn-Wache, K., Hoffmann, T., Nishimura, E., Pederson, R.A. and McIntosh, C.H., 2000, Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem 275:3827-3834.
5. Lambeir, A.M., Durinx, C., Proost, P., Van Damme, J., Scharpé, S. and DeMeester, I., 2001, Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. FEBS Lett. 507:327-330.
6. Mentlein, R., Gallwitz, B. and Schmidt, W.E., 1993, Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835.
7. Deacon, C.F., Johnsen, A.H. and Holst, J.J., 1995, Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J.Clin.Endocrinol.Metab 80:952-957.
8. Pospisilik, J.A., Hinke, S.A., Pederson, R.A., Hoffmann, T., Rosche, F., Schlenzig, D., Glund, K., Heiser, U., McIntosh, C.H. and Demuth, H.-U., 2001, Metabolism of Glucagon by Dipeptidyl Peptidase IV (CD26). Regul Pept 93(3):133-141.